Crossject Société Anonyme (FRA:74C)

Germany flag Germany · Delayed Price · Currency is EUR
2.095
-0.145 (-6.47%)
At close: Dec 4, 2025
11.67%
Market Cap 114.71M
Revenue (ttm) 4.07M
Net Income (ttm) -11.26M
Shares Out n/a
EPS (ttm) -0.22
PE Ratio n/a
Forward PE 4.80
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume n/a
Open 2.095
Previous Close 2.240
Day's Range 2.095 - 2.095
52-Week Range 0.779 - 2.590
Beta n/a
RSI 39.65
Earnings Date Dec 24, 2025

About Crossject Société Anonyme

Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, needle-free, pre-filled, single-use auto-injector. Its product pipeline includes Midazolam for epileptic seizure; Naloxone for opioid overdose; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster headaches, as well as Hydrocortisone for acute adrenal crisis and Methotrexate for the treatment of rheumatoid arthritis. In addition, the company is dev... [Read more]

Industry Surgical and Medical Instruments and Apparatus
Founded 2001
Employees 102
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 74C
Full Company Profile

Financial Performance

In 2024, Crossject Société Anonyme's revenue was 4.12 million, an increase of 6.28% compared to the previous year's 3.87 million. Losses were -12.80 million, 48.1% more than in 2023.

Financial Statements

News

There is no news available yet.